HRP20120170T1 - Nova upotreba u terapiji kod liječenja leukemije - Google Patents

Nova upotreba u terapiji kod liječenja leukemije Download PDF

Info

Publication number
HRP20120170T1
HRP20120170T1 HR20120170T HRP20120170T HRP20120170T1 HR P20120170 T1 HRP20120170 T1 HR P20120170T1 HR 20120170 T HR20120170 T HR 20120170T HR P20120170 T HRP20120170 T HR P20120170T HR P20120170 T1 HRP20120170 T1 HR P20120170T1
Authority
HR
Croatia
Prior art keywords
intended
compound
administration
accordance
followed
Prior art date
Application number
HR20120170T
Other languages
English (en)
Croatian (hr)
Inventor
Bourrie Bernard
Casellas Pierre
Original Assignee
Sanofi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38268928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20120170(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi filed Critical Sanofi
Publication of HRP20120170T1 publication Critical patent/HRP20120170T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HR20120170T 2006-12-28 2007-12-27 Nova upotreba u terapiji kod liječenja leukemije HRP20120170T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0611492A FR2910813B1 (fr) 2006-12-28 2006-12-28 Nouvelle utilisation therapeutique pour le traitement des leucemies
PCT/FR2007/002171 WO2008102075A2 (fr) 2006-12-28 2007-12-27 Nouvelle utilisation therapeutique pour le traitement des leucemies

Publications (1)

Publication Number Publication Date
HRP20120170T1 true HRP20120170T1 (hr) 2012-03-31

Family

ID=38268928

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20120170T HRP20120170T1 (hr) 2006-12-28 2007-12-27 Nova upotreba u terapiji kod liječenja leukemije

Country Status (39)

Country Link
US (1) US8236811B2 (sr)
EP (1) EP2107906B1 (sr)
JP (1) JP5317987B2 (sr)
KR (1) KR101458233B1 (sr)
CN (1) CN101568338B (sr)
AR (1) AR064550A1 (sr)
AT (1) ATE534392T1 (sr)
AU (1) AU2007347370B2 (sr)
BR (1) BRPI0720963A2 (sr)
CA (1) CA2672716C (sr)
CL (1) CL2007003846A1 (sr)
CO (1) CO6190610A2 (sr)
CR (1) CR10881A (sr)
CY (1) CY1112443T1 (sr)
DK (1) DK2107906T3 (sr)
EA (1) EA016873B1 (sr)
EC (1) ECSP099449A (sr)
ES (1) ES2377843T3 (sr)
FR (1) FR2910813B1 (sr)
GT (1) GT200900168A (sr)
HR (1) HRP20120170T1 (sr)
JO (1) JO2748B1 (sr)
MA (1) MA31100B1 (sr)
MX (1) MX2009007054A (sr)
MY (1) MY148515A (sr)
NI (1) NI200900129A (sr)
NO (1) NO20092496L (sr)
NZ (1) NZ577991A (sr)
PE (1) PE20081548A1 (sr)
PL (1) PL2107906T3 (sr)
PT (1) PT2107906E (sr)
RS (1) RS52162B (sr)
SI (1) SI2107906T1 (sr)
SV (1) SV2009003315A (sr)
TN (1) TN2009000234A1 (sr)
TW (1) TWI433678B (sr)
UA (1) UA97505C2 (sr)
WO (1) WO2008102075A2 (sr)
ZA (1) ZA200904478B (sr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2948568B1 (fr) * 2009-07-30 2012-08-24 Sanofi Aventis Formulation pharmaceutique
EP2638911A1 (en) * 2012-03-14 2013-09-18 Sanofi Novel combinations for treating acute myeloid leukaemia or chronic myeloid leukaemia
CN105813635A (zh) * 2013-12-13 2016-07-27 诺华股份有限公司 药物剂型
WO2021061874A2 (en) * 2019-09-23 2021-04-01 President And Fellows Of Harvard College Methods and compositions for treating acute myeloid leukemia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1171218A (en) 1967-11-09 1969-11-19 Parke Davis & Co New Heterocyclic Amine Compounds and Methods for their Production
IL115256A0 (en) 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
MX9702245A (es) 1994-11-14 1997-06-28 Warner Lambert Co Seis-aril-pirido(2,3-d)pirimidinas y naftiridinas para inhibir la proliferacion celular mediada por la proteina cinasa tirosina.
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US5620981A (en) 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
US7115750B1 (en) 1999-09-20 2006-10-03 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonist
WO2001055147A1 (en) * 2000-01-25 2001-08-02 Warner-Lambert Company PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS
EE200200506A (et) 2000-03-06 2004-02-16 Warner-Lambert Company 5-alküülpürido[2,3-d]pürimidiinid kui türosiinkinaasi inhibiitorid
JP2004519422A (ja) 2000-08-04 2004-07-02 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー ２−（４−ピリジル）アミノ−６−ジアルコキシフェニルピリド〔２，３−ｄ〕ピリミジン−７−オン
AU2002324450A1 (en) * 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidines and uses thereof
WO2004063195A1 (en) 2003-01-03 2004-07-29 Sloan-Kettering Institute For Cancer Research Pyridopyrimidine kinase inhibitors
TW200502236A (en) 2003-03-28 2005-01-16 Hoffmann La Roche Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
WO2005105097A2 (en) 2004-04-28 2005-11-10 Gpc Biotech Ag Pyridopyrimidines for treating inflammatory and other diseases
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
UY29017A1 (es) 2004-07-16 2006-02-24 Boehringer Ingelheim Int Inhibidores de polimerasa viral
FR2887882B1 (fr) * 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.

Also Published As

Publication number Publication date
AR064550A1 (es) 2009-04-08
PL2107906T3 (pl) 2012-04-30
GT200900168A (es) 2010-03-19
NZ577991A (en) 2012-01-12
JO2748B1 (en) 2014-03-15
BRPI0720963A2 (pt) 2014-03-18
MA31100B1 (fr) 2010-01-04
FR2910813A1 (fr) 2008-07-04
DK2107906T3 (da) 2012-03-19
JP2010514743A (ja) 2010-05-06
CA2672716C (fr) 2013-05-28
NI200900129A (es) 2011-12-13
ZA200904478B (en) 2010-08-25
CL2007003846A1 (es) 2009-01-23
EA016873B1 (ru) 2012-08-30
CN101568338B (zh) 2011-11-23
TWI433678B (zh) 2014-04-11
US8236811B2 (en) 2012-08-07
TN2009000234A1 (fr) 2010-10-18
WO2008102075A3 (fr) 2008-12-11
MY148515A (en) 2013-04-30
CY1112443T1 (el) 2015-12-09
SV2009003315A (es) 2010-02-05
SI2107906T1 (sl) 2012-03-30
TW200833343A (en) 2008-08-16
RS52162B (sr) 2012-08-31
PT2107906E (pt) 2012-03-05
CN101568338A (zh) 2009-10-28
EP2107906A2 (fr) 2009-10-14
JP5317987B2 (ja) 2013-10-16
CA2672716A1 (fr) 2008-08-28
NO20092496L (no) 2009-07-23
AU2007347370B2 (en) 2013-05-23
PE20081548A1 (es) 2009-01-04
ATE534392T1 (de) 2011-12-15
UA97505C2 (ru) 2012-02-27
HK1138189A1 (en) 2010-08-20
KR101458233B1 (ko) 2014-11-04
CR10881A (es) 2009-08-12
KR20090103899A (ko) 2009-10-01
US20090298790A1 (en) 2009-12-03
EP2107906B1 (fr) 2011-11-23
ES2377843T3 (es) 2012-04-02
FR2910813B1 (fr) 2009-02-06
MX2009007054A (es) 2009-08-12
EA200970639A1 (ru) 2010-04-30
WO2008102075A2 (fr) 2008-08-28
CO6190610A2 (es) 2010-08-19
AU2007347370A1 (en) 2008-08-28
ECSP099449A (es) 2009-07-31

Similar Documents

Publication Publication Date Title
PH12022553530A1 (en) 1'-cyano nucleoside analogs and uses thereof
MY148571A (en) Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines
ES2422557T3 (es) Compuestos y composiciones como moduladores de la ruta Hedgehog
NZ591312A (en) Treatment of pediatric acute lymphoblastic leukemia with a CD19 CD3 bispecific single chain antibody construct
EP1749830A4 (en) CURCUMOL DERIVATIVES, COMPOSITION COMPRISING THE SAME, AND THEIR USE FOR THE PRODUCTION OF MEDICAMENTS
HRP20110245T1 (hr) Derivati pirazolopirimidina kao inhibitori o ciklinu ovisne kinaze
MY150717A (en) Long term treatment of hiv-infection with tmc278
BRPI0611705A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de composto
DE60143911D1 (de) Antitumorzusammensetzungen welche ecteinascidin 743 enthalten
IL273398B2 (en) History of 4'-fluoro-2'-methyl-modified nucleosides as inhibitors of HCV RNA replication
CY1114163T1 (el) Μεθοδοι χρησεως ανταγωνιστων αγγειοπιεσινης με παραγοντες χημειοθεραπειας ανθρακυκλινης για να μειωνεται καρδιοτοξικοτητα ή/και να βελτιωνεται επιβιωση
MY145647A (en) (4-hydroxy-2-oxo-3h-benzothiazol-7-yl)ethylamine derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy (for example in the treatment of respiratory disease states)
AR064543A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
CO6190610A2 (es) Nueva utilizacion terapeutica para el tratamiento de las leucemias
BRPI0407679A (pt) sulfamatos de estra-1,3,5(10)-trien-3-ila 2-substituìdos ativos antitumor
WO2007056236A3 (en) Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
TW200719899A (en) Tricyclic azole derivatives, their manufacture and use as pharmaceutical agents
MX2007009312A (es) Preparaciones inyectables de diclofenaco y sus sales farmaceuticamente aceptables.
WO2007081540A3 (en) Tylophorine analogs as antitumor agents
CL2014002434A1 (es) Combinacion que comprende el compuesto n-[2-(2,1,3-benzotiadiazol-5-ilamino)-6-(2,6-diclorofenil)pirido[2,3-d]pirimidin-7-il]-n'-(1,1-dimetiletil)-urea (a) con citarabina (b); kit farmaceutico; uso en el tratamiento de leucemia mieloide aguda y leucemia mieloide crónica.
WO2007075650A3 (en) Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders
TH100294A (th) การใช้ประโยชน์ในการรักษาโรคชนิดใหม่สำหรับการรักษาลูคีเมีย
TW200736220A (en) Pyridylsulfonamide derivatives, their manufacture and use as pharmaceutical agents
Springer et al. Bacteria in cancer therapy
WO2010146585A4 (en) Tellurium-containing compounds for treating viral infections